Oral insulin therapy fails to prevent type 1 diabetes, but some see disease delay

06/15/2017

In adults with two or more antibodies predicting the development of type 1 diabetes, treatment with daily oral insulin therapy did not prevent development of the disease, but a small subset experienced a 31-month delay in clinical diabetes development.

“It’s important to note, this [delay in disease development] was not the primary endpoint, nor the primary group, so overall, the [trial] results were negative,” Carla J. Greenbaum, MD, of the Benaroya Research Institute in Seattle, said during a press conference announcing the findings. “Nonetheless, this dramatic result in the secondary analysis remains something we wish to follow up on.”

In a previous randomized, placebo-controlled trial involving participants with what is often called “stage 1” type 1 diabetes — relatives of patients with type 1 diabetes with positive antibodies predicting the disease but normal glucose tolerance — treatment with 7.5 mg daily oral insulin did not delay or prevent the development of clinical type 1 diabetes in the cohort, Greenbaum said. However, in a post hoc analysis, researchers identified a subgroup with specific antibodies who did experience a delay in disease development compared with those assigned placebo.

Read the full article on Healio.com.

Learn the Latest

A sample printed newsletterSign up for our news & updates and learn the latest in the fight against autoimmune diseases.

Sign up today